Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil CountsSurya P. Bhatt, Raolat M. Abdulai, Stephanie A. Christenson et al.|New England Journal of Medicine|2023Cited by 452
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of AgeMirna Chehade, Jennifer Maloney, Evan S. Dellon et al.|New England Journal of Medicine|2024Cited by 107
A Phase 2/3 Study To Assess The Efficacy And Safety Of Dupilumab Versus Placebo In Adults And Adolescents With Eosinophilic Gastritis With Or Without Eosinophilic DuodenitisEvan S. Dellon, Arsalan Shabbir, Marc E. Rothenberg et al.|Journal of Allergy and Clinical Immunology|2024Cited by 1